Assertio Therapeutics (ASRT) Tops Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2018 Financial Results
March 6, 2019 4:02 PM EST-- Reports Neurology Franchise Annual Net Sales of $110.3 million, at the High End of Guidance Range --
-- Files NDA for Long-Acting Cosyntropin and Receives FDA Notification of Acceptance --
-- Issues Full-Year 2019 Guidance for Earnings and Neurology Franchise Net Sales --
LAKE FOREST, Ill., March 06, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today reported financial results for the fourth quarter and year ended December 31, 2018, and provided an update on its business performance and strategic initiatives.
... More